为您找到"
im132
"相关结果约100,000,000个
Introduction: We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Methods: Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or ...
esmo.org IMpower132: efficacy of atezolizumab + carboplatin/cisplatin + pemetrexed as 1L treatment in key subgroups with stage IV non-squamous NSCLC
In the 45 ≤ CCr < 60 mL/min subgroup in each study, Grade ≥ 3 TRAEs were 78.0% and 42.9% in IM130, and 57.1% and 72.0% in IM132. Conclusions The post hoc analysis showed that the combination therapy of PtD and ATZ demonstrated favorable PFS and OS in pts aged ≥ 75 years in the integrated population with tolerable safety.
IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open-label, IMpower132 study included age ≥18 y, histologically or cytologica …
TPS1115Background: Atezo blocks the interaction of PD-L1 with receptors PD-1 and B7.1, restoring anti-tumor immunity. PD-L1 pathway inhibitors may be synergistic with CT. In a phase 1b study in mTNBC, atezo + nab-paclitaxel showed durable confirmed ...
The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC significantly improved progression-free survival and showe …
(IM132: carboplatin or cisplatin and pemetrexed with ATZ) were utilized for the in-tegrated analysis. The efficacy and safety were evaluated in pts who were judged to be eligible based on the research protocol and ethics review committee approval. Kaplan-Meier estimates and hazard ratios for PFS and OS were provided.
Background. The Phase III IMpower132 study, evaluating first line pemetrexed plus carboplatin/cisplatin with or without atezolizumab in Stage IV non-squamous NSCLC without EGFR or ALK driver mutations, has met its PFS endpoint with an HR of 0.60 (95% CI: 0.49, 0.72; P . 0.0001; Papadimitrakopoulou, WCLC 2018).. Here we present the final OS and safety results.
RAF Typhoon of 3 Squadron fires ASRAAM in 2007 ASRAAM at ILA 2006. The Advanced Short Range Air-to-Air Missile (ASRAAM), also known by its United States designation AIM-132, is an imaging infrared homing air-to-air missile, produced by MBDA UK, that is designed for close-range combat.It is in service in the Royal Air Force (RAF), replacing the AIM-9 Sidewinder.
IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer (NSCLC).